Overview

Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Phase II trial of combination therapy with S-1, irinotecan, and bevacizumab (SIRB) in patients with unresectable or recurrent colorectal cancer
Phase:
Phase 2
Details
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Treatments:
Bevacizumab
Camptothecin
Irinotecan